查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1413901

膠原蛋白疾病血管疾病市場：按產品、適應症和最終用途 - 全球預測 2024-2030

Collagen Vascular Diseases Market by Product (Diagnosis, Treatments), Indication (Ankylosing Spondylitis, Dermatomyositis, Polyarteritis Nodosa), End-Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

膠原病血管疾病市場規模預計2023年為298.3億美元，2024年達322.1億美元，預計2030年將達535.1億美元，複合年成長率為8.70%。

全球膠原血管疾病市場

主要市場統計
基準年[2023] 298.3億美元
預測年份 [2024] 322.1億美元
預測年份 [2030] 535.1億美元
複合年成長率（%） 8.7%
膠原蛋白疾病血管疾病市場-IMG1

膠原血管疾病是一組涉及支持器官和身體其他部位的富含蛋白質的組織的疾病。這種結締組織對於皮膚、肌腱、骨骼、軟骨和血管的強度、彈性和結構至關重要。膠原病血管疾病可能是遺傳性的，也可能是由過度活躍的免疫系統引起的，導致身體攻擊自身組織的自體自體免疫疾病。這些疾病通常具有通用特徵，包括導致受影響器官和組織受損和功能障礙的發炎。這一類包括多種疾病，包括類風濕性關節炎、硬皮症、全身性紅斑性狼瘡、多發性肌炎、皮肌炎和全身性硬化症。膠原病血管疾病市場涵蓋醫療解決方案的需求和供應，例如針對影響結締組織的疾病的診斷、治療、治療和服務。該市場的應用包括臨床診斷、治療和持續的患者管理。最終使用者通常是醫療機構，例如醫院、診所、風濕病中心和居家照護機構。該市場也為研究和學術機構以及參與開發新治療方法的製藥和生物技術公司提供服務。影響膠原蛋白血管疾病市場需求的關鍵因素是：人們對膠原蛋白血管疾病的認知和理解不斷提高、全球自體自體免疫疾病盛行率上升、醫療保健基礎設施的改善以及醫療服務的可及性。然而，他們面臨挑戰，例如與先進治療和藥物相關的高成本，以及嚴格的政府法規和核准流程。同時，對膠原血管疾病的需求帶來了一些快速成長的機會，包括基因療法和幹細胞療法的不斷進步，以及遠端醫療、行動健康應用和穿戴式裝置在患者管理中的採用。

區域洞察

美國因其完善的醫療基礎設施、患者意識以及自體自體免疫疾病的高盛行率而成為心血管疾病的重要市場。專注於技術創新的大型製藥企業的存在和政府的支持政策正在促進市場的擴張。在南美洲，隨著醫療保健的改善和人們對這種疾病的認知不斷提高，膠原蛋白血管疾病市場正在擴大。政府加強醫療保健服務和醫學研究國際合作的措施預計將進一步提振市場。歐盟對 KEYWORD 的需求的特徵是全民健保系統的可用性以及對研究和開發的重視。嚴格的藥品核准規定確保了高標準的醫療服務。該地區的消費者期待最先進的治療設施，並受到治療的功效和安全性的驅動。包括膠原血管疾病在內的自體免疫疾病在中東呈上升趨勢，發展中的醫療保健產業高度依賴國際指南和藥物。非洲治療膠原血管疾病的能力各不相同，許多地區這些疾病的盛行率很高，而且缺乏先進的治療方法。隨著向現代醫療保健體系的過渡，中國市場正在迅速擴張，政府和私營部門對醫療保健的投資不斷增加，全球藥品的獲取情況也有所改善，影響了客戶的需求。日本市場反映了醫療保健領域技術整合的高水平，消費者基礎傾向於創新和護理品質。

FPNV定位矩陣

FPNV定位矩陣對於評估膠原血管疾病市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對膠原病血管疾病市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-膠原蛋白血管疾病市場的市場規模和預測是多少？

2-在膠原病血管疾病市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3-膠原血管疾病市場的技術趨勢和法律規範是什麼？

4-膠原病血管疾病市場主要供應商的市場佔有率是多少？

5-進入膠原血管疾病市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高對膠原血管疾病的認知與理解
      • 全球自體自體免疫疾病發生率上升
      • 改善醫療基礎設施並增加獲得醫療服務的機會
    • 抑制因素
      • 與先進治療和藥物相關的高成本
    • 機會
      • 基因治療和幹細胞治療的持續進展
      • 採用遠端醫療、行動醫療應用和穿戴式裝置進行病患管理
    • 任務
      • 嚴格的政府法規和核准流程
  • 市場區隔分析
    • 產品：切片檢查套件在膠原血管疾病的使用增加
    • 適應症：擴大用作皮肌炎的適應症
    • 最終用途：在診斷中心和實驗室中廣泛使用，以診斷各種健康狀況
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章膠原蛋白疾病血管疾病市場：依產品

  • 診斷
    • 切片檢查
    • 驗血
    • 超音波心臟檢查
    • 影像檢查
    • 尿液檢查
  • 治療方法
    • 藥品
    • 物理治療

第7章膠原蛋白疾病血管疾病市場（按適應症）

  • 僵直性脊椎炎
  • 皮肌炎
  • 結節性多動脈炎
  • 多發性肌炎
  • 乾癬性關節炎
  • 復發性多發性軟骨炎
  • 類風濕性關節炎
  • 硬皮症
  • 全身性紅斑性狼瘡
  • 血管炎

第8章膠原病血管疾病市場：依最終用途分類

  • 診斷中心和實驗室
  • 醫院和診所

第9章 北美和南美膠原蛋白疾病血管疾病市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區膠原蛋白疾病血管疾病市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲膠原病血管疾病市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析
    • 合約、合作和夥伴關係
    • 新產品發布和功能增強
    • 獎項/獎勵/擴展

第13章競爭產品組合

  • 主要公司簡介
    • Abbott Laboratories
    • AbbVie Inc.
    • Apollo Health and Lifestyle Limited
    • Augurex Life Sciences Corporation
    • Bayer AG
    • Beckman Coulter, Inc.
    • Bio-Rad Laboratories Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb
    • Eli Lilly and Company
    • Exagen Inc.
    • F. Hoffmann-La Roche Ltd
    • Getinge AB
    • Gilead Sciences, Inc.
    • Illumina, Inc.
    • Laboratory Corporation of America Holdings
    • LeMaitre Vascular, Inc.
    • Merck KGaA
    • Novartis AG
    • PerkinElmer, Inc.
    • Pfizer Inc,
    • QIAGEN GmbH
    • Siemens AG
    • Thermo Fisher Scientific, Inc.
    • Trinity Biotech PLC
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-144C638C8F84

[195 Pages Report] The Collagen Vascular Diseases Market size was estimated at USD 29.83 billion in 2023 and expected to reach USD 32.21 billion in 2024, at a CAGR 8.70% to reach USD 53.51 billion by 2030.

Global Collagen Vascular Diseases Market

KEY MARKET STATISTICS
Base Year [2023] USD 29.83 billion
Estimated Year [2024] USD 32.21 billion
Forecast Year [2030] USD 53.51 billion
CAGR (%) 8.7%
Collagen Vascular Diseases Market - IMG1

Collagen vascular diseases comprise a group of disorders that involve the protein-rich tissue that supports organs and other parts of the body. This connective tissue is essential for the strength, elasticity, and structure of skin, tendons, bones, cartilage, and blood vessels. Collagen vascular diseases can be hereditary or caused by an overactive immune system, resulting in autoimmune conditions where the body attacks its own tissues. These diseases often share common features, including inflammation, which can damage and dysfunction of affected organs and tissues. The category encompasses a variety of conditions, including rheumatoid arthritis, scleroderma, systemic lupus erythematosus, polymyositis, dermatomyositis, and systemic sclerosis, among others. The market for collagen vascular diseases encompasses the demand and supply of medical solutions, including diagnostics, treatments, therapeutics, and services targeted towards diseases that affect connective tissue. Applications for this market include clinical diagnostics, therapeutic treatments, and ongoing patient management. End-users are typically healthcare facilities like hospitals, clinics, specialized rheumatology centers, and home care settings. This market also serves research and academic institutions and pharmaceutical and biotechnology companies involved in the development of new treatments. The key factors influencing the need for the collagen vascular diseases market include growing awareness and understanding of collagen vascular diseases, rising incidence of autoimmune diseases globally, improved healthcare infrastructure, and increased accessibility to medical services. However, the market faces challenges, such as high costs associated with advanced treatments and medications and stringent government regulations and approval processes. On the other hand, the need for collagen vascular diseases presents several burgeoning opportunities, such as ongoing advancements in gene and stem cell therapies and the adoption of telemedicine, mobile health applications, and wearables for patient management.

Regional Insights

The United States represents a significant market for collagen vascular diseases (CVDs), driven by a well-established healthcare infrastructure, patient awareness, and a high incidence of autoimmune diseases. The presence of leading pharmaceutical companies focusing on innovation, coupled with supportive government policies, contributes to market expansion. In South America, the collagen vascular diseases market is expanding as healthcare access improves and the population becomes more aware of these diseases. Government initiatives to strengthen healthcare provision and international collaborations for medical research are expected to propel the market further. The EU's need for collagen vascular diseases is characterized by the availability of universal healthcare systems and a strong focus on research and development. Stringent regulations regarding drug approvals ensure a high standard of care. Consumers in this region expect state-of-the-art treatment facilities and are driven by the effectiveness and safety profiles of treatments. The Middle East is experiencing a rise in autoimmune disorders, including collagen vascular diseases, and due to a developing healthcare sector, there is a reliance on international guidelines and medications. Africa's capacity to manage collagen vascular diseases is varied, with a greater prevalence of these conditions and a scarcity of advanced treatments in many regions. China's market is rapidly expanding with a shift towards modern healthcare systems, and increased investment in healthcare by the government and private sector, paired with greater access to global pharmaceuticals, is influencing customer needs. Japan's market reflects a high degree of technological integration in healthcare, with a consumer base inclined towards innovation and treatment quality.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Collagen Vascular Diseases Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Collagen Vascular Diseases Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Collagen Vascular Diseases Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Apollo Health and Lifestyle Limited, Augurex Life Sciences Corporation, Bayer AG, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd, Getinge AB, Gilead Sciences, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, LeMaitre Vascular, Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer Inc,, QIAGEN GmbH, Siemens AG, Thermo Fisher Scientific, Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Collagen Vascular Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Diagnosis
      • Biopsy
      • Blood Test
      • Echocardiogram
      • Imaging Tests
      • Urinalysis
    • Treatments
      • Medications
      • Physical Therapy
  • Indication
    • Ankylosing Spondylitis
    • Dermatomyositis
    • Polyarteritis Nodosa
    • Polymyositis
    • Psoriatic Arthritis
    • Relapsing Polychondritis
    • Rheumatoid Arthritis
    • Scleroderma
    • Systemic Lupus Erythematosus
    • Vasculitis
  • End-Use
    • Diagnostic Centers & Laboratories
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Collagen Vascular Diseases Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Collagen Vascular Diseases Market?

3. What are the technology trends and regulatory frameworks in the Collagen Vascular Diseases Market?

4. What is the market share of the leading vendors in the Collagen Vascular Diseases Market?

5. Which modes and strategic moves are suitable for entering the Collagen Vascular Diseases Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Collagen Vascular Diseases Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness and understanding of collagen vascular diseases
      • 5.1.1.2. Rising incidence of autoimmune diseases globally
      • 5.1.1.3. Improved healthcare infrastructure and increased accessibility to medical services
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced treatments and medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in gene and stem cell therapies
      • 5.1.3.2. Adoption of telemedicine, mobile health applications, and wearables for patient management
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing usage of biopsy kits in collagen vascular diseases
    • 5.2.2. Indication: Increasing utilization for indicating dermatomyositis
    • 5.2.3. End-Use: Expanding usage among diagnostic centers & laboratories to diagnose various health conditions
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Collagen Vascular Diseases Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnosis
    • 6.3.1. Biopsy
    • 6.3.2. Blood Test
    • 6.3.3. Echocardiogram
    • 6.3.4. Imaging Tests
    • 6.3.5. Urinalysis
  • 6.3. Treatments
    • 6.4.1. Medications
    • 6.4.2. Physical Therapy

7. Collagen Vascular Diseases Market, by Indication

  • 7.1. Introduction
  • 7.2. Ankylosing Spondylitis
  • 7.3. Dermatomyositis
  • 7.4. Polyarteritis Nodosa
  • 7.5. Polymyositis
  • 7.6. Psoriatic Arthritis
  • 7.7. Relapsing Polychondritis
  • 7.8. Rheumatoid Arthritis
  • 7.9. Scleroderma
  • 7.10. Systemic Lupus Erythematosus
  • 7.11. Vasculitis

8. Collagen Vascular Diseases Market, by End-Use

  • 8.1. Introduction
  • 8.2. Diagnostic Centers & Laboratories
  • 8.3. Hospitals & Clinics

9. Americas Collagen Vascular Diseases Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Collagen Vascular Diseases Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Collagen Vascular Diseases Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player
    • 12.3.1. Agreement, Collaboration, & Partnership
      • 12.3.1.1. Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
    • 12.3.2. New Product Launch & Enhancement
      • 12.3.2.1. American College of Rheumatology Launches New Toolkit Aimed at Measuring Rheumatoid Arthritis Outcomes
    • 12.3.3. Award, Recognition, & Expansion
      • 12.3.3.1. FDA Approves First Tocilizumab Biosimilar For Treatment Of Rheumatoid Arthritis, JIA

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. AbbVie Inc.
    • 13.1.3. Apollo Health and Lifestyle Limited
    • 13.1.4. Augurex Life Sciences Corporation
    • 13.1.5. Bayer AG
    • 13.1.6. Beckman Coulter, Inc.
    • 13.1.7. Bio-Rad Laboratories Inc.
    • 13.1.8. Boehringer Ingelheim International GmbH
    • 13.1.9. Bristol-Myers Squibb
    • 13.1.10. Eli Lilly and Company
    • 13.1.11. Exagen Inc.
    • 13.1.12. F. Hoffmann-La Roche Ltd
    • 13.1.13. Getinge AB
    • 13.1.14. Gilead Sciences, Inc.
    • 13.1.15. Illumina, Inc.
    • 13.1.16. Laboratory Corporation of America Holdings
    • 13.1.17. LeMaitre Vascular, Inc.
    • 13.1.18. Merck KGaA
    • 13.1.19. Novartis AG
    • 13.1.20. PerkinElmer, Inc.
    • 13.1.21. Pfizer Inc,
    • 13.1.22. QIAGEN GmbH
    • 13.1.23. Siemens AG
    • 13.1.24. Thermo Fisher Scientific, Inc.
    • 13.1.25. Trinity Biotech PLC
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. COLLAGEN VASCULAR DISEASES MARKET RESEARCH PROCESS
  • FIGURE 2. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. COLLAGEN VASCULAR DISEASES MARKET DYNAMICS
  • FIGURE 7. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. COLLAGEN VASCULAR DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 8. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 15. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DERMATOMYOSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYARTERITIS NODOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYMYOSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RELAPSING POLYCHONDRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SCLERODERMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 240. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 241. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. COLLAGEN VASCULAR DISEASES MARKET LICENSE & PRICING